Breast Cancer
Opinion
Oophorectomy for premenopausal breast cancer
In this month’s Gynecologic Oncology Consult, Dr. Emma Rossi discusses ovarian ablation and removal in treatment of breast cancer.
Conference Coverage
Adjuvant trastuzumab for breast cancer: 6 months may suffice
Disease-free survival was similarly high whether women received adjuvant trastuzumab for the current standard of 12 months or for just 6 months....
From the Journals
Female cancer researchers receive less funding than male counterparts
In an analysis of cancer research funding awards to U.K. institutions between 2000 and 2013, only 31% were awarded to female primary investigators...
Feature
2017 notches up some landmark approvals
From the Journals
Breast cancer: More pathogenic variants detected as multiple-gene sequencing takes over
Multiple-gene sequencing has rapidly replaced BRCA1/2-only testing in community practice.
From the Journals
Intravenous antiemetic combination is well tolerated
An intravenous combination of two antiemetic medications is as well tolerated as is the oral version for managing chemotherapy-related nausea and...
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
How We Do It
Integrating survivorship care planning in radiation oncology workflow
Conference Coverage
Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients
AUSTIN, TEX. – BRCA testing could add more than a decade of life to women at risk for ovarian cancer.
From the Journals
Early breast cancer: Patients report favorable quality of life after partial breast irradiation
Moreover, breast symptom scores were worse for whole breast radiation in the study.
From the Journals
Hormone therapy raises diabetes risk in breast cancer survivors
Tamoxifen and aromatase inhibitors were associated with increased risk for diabetes in a case-cohort study in Israel.